Skip to main content

Corbus Pharmaceuticals Holdings, Inc 8-K, filed Nov 16, 2026

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

8-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 8-K

Corbus Pharmaceuticals Holdings, Inc filed this 8-K on November 16, 2026.

Corbus Pharmaceuticals Holdings, Inc. said CRB-913 produced significant mean weight loss at 20 mg, 40 mg and 60 mg; the highest dose achieved 5% after 12 weeks. Adverse-event discontinuation was 8.3%, with no serious or severe psychiatric adverse events. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits